Dataset Information


Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy.

ABSTRACT: Castration-resistant prostate cancer (CRPC) is a near uniformly fatal form of prostate cancer; however, information on time to development and predictors for progression to CRPC is limited. We report a detailed longitudinal study for development of CRPC in men initially treated with external beam radiotherapy (EBRT).During 1991-2008, 2,478 patients with clinically localized prostate cancer were treated with dose-escalated EBRT at a single institution. The primary objective was to determine predictors of CRPC among men who failed definitive EBRT and progressed to salvage androgen-deprivation therapy (ADT). CRPC was defined as castrate levels of testosterone (<50?ng/dl) with progressive biochemical or radiographic disease.For the entire cohort (n?=?2,478), the 10-year cumulative incidence rate for developing CRPC was 9.9%. For those that progressed to salvage ADT (n?=?362), the 7-year cumulative incidence rates for developing CRPC from time of salvage ADT was 33.7%. Amongst this cohort, multivariable analysis demonstrated that PSA doubling-time (continuous; hazard ratio [HR], 0.98 [0.97-0.99], P?

PROVIDER: S-EPMC5522730 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5546832 | BioStudies
| S-EPMC7493337 | BioStudies
| S-EPMC7402025 | BioStudies
2019-01-01 | S-EPMC6474628 | BioStudies
| S-EPMC8432826 | BioStudies
| S-EPMC5002994 | BioStudies
| S-EPMC8251338 | BioStudies
| S-EPMC7460336 | BioStudies
| S-EPMC7606809 | BioStudies
| S-EPMC8176613 | BioStudies